C-AQQMSenisca
RNA splicing, senotherapeutics, oligonucleotides
modulatingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-AQQM
C-AQQMC-AQQMRNA splicing, senotherapeutics, oligonucleotides
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Senisca RNA splicing, senotherapeutics, oligonucleotides
SENISCA is a biotech spin-out from the University of Exeter focused on modulating RNA biology to treat age-related disease. Its founders identified dysregulated RNA splicing as a druggable hallmark of ageing and are developing RNA senotherapeutics to reprogram senescent cells. The company describes oligonucleotide-based therapeutic approaches intended to reset splicing factor levels and target causes of age-related disease.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Senisca — Early mechanism · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic